Últimas noticias sobre WF Holding (NASDAQ:WFF) Bolsa

WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.

WF Holding Ltd

<a href="https://www.globenewswire.com/Tracker?data=oXeEq9J56C70uDyHmrKrFfL2Tmo6pMSGMRLBwqpdKLMjXBSyB-jMxljZ9Fri-RUm5BtwZR-HLedZnsEenONOgtQY1Hf_af0Tiw5MMT-JZHs=">Genius Group Limited</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNS#NYSE">GNS</a>) ("Genius Group" or the "Company"), a leading AI-powered, Bitcoin-first education group, today announced that its Board of Directors have approved a distribution plan from the proceeds of any and all future legal wins, with net proceeds divided equally for distribution to shareholders and purchase of Bitcoin for its Bitcoin Treasury.
Genius Group's CEO, Roger Hamilton said "The Company has two legal cases, one filed and one pending, in which we are seeking combined damages of over $1 billion. As both lawsuits are being pursued by the Company to recover damages caused by third parties directly to our shareholders, the Board believes that 100% of any proceeds from the successful outcome of these cases should be directly distributed or reinvested for the benefit of shareholders."
The Company currently has filed a complaint under the Racketeer Influenced and Corrupt Organizations Act (RICO), in the United States District Court, Southern District of Florida against Peter Ritz and Michael Moe as the controlling officers and directors of LZGI International, Inc ("LZG") and against Michael Carter and John Clayton, seeking damages of over $750 million (which includes treble damages potentially recoverable under federal statute) caused by the defendants to Genius Group. (Case No: 1:25-cv-21496)
The Company also has an upcoming lawsuit alleging naked short selling and evidence of spoofing against certain parties, led by Wes Christian of Christian Attar, with alleged damages calculated at between $251.3 million and $262.7 million following the initial analysis of the Company's share trading data in 2023. The Company's legal team has continued detailed tracking of all trades in the Company for 2024 and 2025, and the filing, which is currently in final review pending filing, will include an updated damages amount which the Company anticipates to be significantly higher than the 2023 calculation based on the information provided.
Whilst there is no guarantee on the final outcome of either case, the time frames of the cases or on the amount of damages that the Company may win or recover, in the event that the Company is successful in recovering any damages, the Board has agreed to the following distribution:
<ul>
<li>Distribution of 50% of any net damages recovered by way of special dividend to shareholders, to be issued once any net damages have been recovered. &nbsp;</li>
<li>Investment of 50% of any net damages recovered in purchasing Bitcoin for the Company's Bitcoin Treasury, to be purchased once any net damages have been recovered. &nbsp;</li>
</ul>
In the event there are multiple instances of damage recovery, the distribution will apply to each instance. Net damages will be damages received by the Company net of legal fees, recovery fees and tax. Any and all distributions will be subject to applicable rules by the relevant regulatory bodies including the SEC, NYSE and Singapore law.

News

Dividends

Genius Group Board Approves 50/50 Split Of Future Legal Win Proceeds, Half As Shareholder Dividend, Half For Bitcoin Treasury Purchases; Potential Claims Exceed $1B

Morgan Stanley analyst Vincent Sinisi maintains Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Equal-Weight and raises the price target from $60 to $65.

Price Target

Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Nutrien, Raises Price Target to $65

JMP Securities analyst Greg Miller reiterates Equinix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>) with a Market Outperform and maintains $1200 price target.

Reiteration

EQIX

JMP Securities Reiterates Market Outperform on Equinix, Maintains $1200 Price Target

McKesson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>) has outperformed the market over the past 15 years by 4.58% on an annualized basis producing an average annual return of 17.22%. Currently, McKesson has a market capitalization of $90.92 billion. 
Buying $100 In MCK: If an investor had bought $100 of MCK stock 15 years ago, it would be worth $1,086.27 today based on a price of $727.91 for MCK at the time of writing.
<h3>McKesson's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750946680_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

UBS analyst Peter Grom maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Sell and lowers the price target from $52 to $49.

UBS Maintains Sell on General Mills, Lowers Price Target to $49

Morgan Stanley analyst Joseph Moore maintains Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) with a Equal-Weight and raises the price target from $98 to $135.

Morgan Stanley Maintains Equal-Weight on Micron Technology, Raises Price Target to $135

JMP Securities analyst Jonathan Wolleben reiterates DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) with a Market Outperform and maintains $21 price target.

DBVT

JMP Securities Reiterates Market Outperform on DBV Technologies, Maintains $21 Price Target

<a href="https://www.benzinga.com/25/05/45535042/recession-odds-tumble-on-kalshi-crypto-based-polymarket-as-trumps-tariff-concerns-subside">Prediction market platform Kalshi</a> has secured a $185 million Series C funding round, pushing the company's valuation to $2 billion.
The round was led by Paradigm and Sequoia, with participation from both new and existing investors.
"Kalshi today is one of the fastest growing companies in America," co-founder and CEO Tarek Mansour <a href="https://www.cnbc.com/video/2025/06/26/kalshi-ceo-on-hitting-2b-valuation-were-one-of-the-fastest-growing-companies-in-america.html">told</a> CNBC in an interview. 
According to Mansour, the platform has seen rapid growth across all major metrics. 
"We 50x'd our user base last year. This year, the user base is growing around 100x, and the number of markets has scaled 15x just from last October," he said.
Kalshi's growth is not only reflected in user numbers but also in financial performance. 
"Our revenue has scaled meaningfully and the company is doing very well on the financial side," Mansour said.
The fresh funding will be used to expand Kalshi's talent pool, scale market offerings, and meet rising demand from brokerages seeking to integrate Kalshi's prediction markets. 
"We've built an incredible talent density in New York," Mansour said, adding that Kalshi is recruiting engineers, traders, economists, and product designers, with many hires coming from both Silicon Valley and Wall Street.
"We cannot compete with the salaries that some hedge funds are paying," Mansour noted, but said equity remains a key part of Kalshi's compensation strategy. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46112072/coinbase-is-the-amazon-of-crypto-services-price-target-boosted-to-510-bernstein">Coinbase Is The &#8216;Amazon Of Crypto Services&#8217;, Price Target Boosted To $510: Bernstein</a>
"People don't join Kalshi for the fancy investors or the money. They join for the mission, what we're building."
Kalshi has also expanded its market offerings, growing from around 100 markets in October to approximately 1,500 today, with plans to double or triple that number by year's end. 
Key growth areas include sports and political prediction markets.
Mansour pointed out that Kalshi's markets had provided real-time pricing that, in some cases, outpaced traditional Wall Street expectations. 
Reflecting on the recent New York City mayoral race, Mansour said, "Our markets were not really caught off guard. Our markets were pricing it."
Kalshi's data also showed interesting demographic splits in trading patterns during the election. 
According to Mansour, women predominantly backed Mamdani, while the support among men was evenly split. 
Younger participants leaned toward Mamdani, while older ones favored Cuomo.
In political prediction markets, Kalshi is already seeing volume around the Democratic primaries.
 Alexandria Ocasio-Cortez and Gavin Newsom are currently leading the odds, according to Mansour. 
&#8220;AOC is around 14%, Newsom is at around 13%, and Buttigieg is below 10%.&#8221;
Asked about confidence in these long-range predictions, Mansour responded, "There's a lot that can happen in three and a half years, but it's a gauge. This is where we're at today and this is what the market thinks."
Mansour also noted a sharp increase in odds for New York Mayor Eric Adams in recent days. 
&#8220;Eric Adams has shot up 400% in the last 36 hours… I always say 24% is 24%. It's not zero. He could pull it off."
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46114220/asias-microstrategy-metaplanet-acquires-additional-1234-bitcoin-as-etfs-extend-12-day-inflow-streak">&#8216;Asia&#8217;s MicroStrategy&#8217; Metaplanet Acquires Additional 1,234 Bitcoin As ETFs Extend 12-Day Inflow Streak</a></li>
</ul>
Image: Shutterstock

Education

Prediction Market Kalshi Raises $185M, Surges To $2B Valuation

<a href="https://www.richmondfed.org/press_room/media_advisories/2025/20250623_barkin_ny#:~:text=Richmond%20Fed%20President%20Tom%20Barkin,%2C%202025%2C%20in%20New%20York.&amp;text=Speech%20is%20scheduled%20for%208,event%20also%20includes%20audience%20Q%26A" title="https://www.richmondfed.org/press_room/media_advisories/2025/20250623_barkin_ny#:~:text=Richmond%20Fed%20President%20Tom%20Barkin,%2C%202025%2C%20in%20New%20York.&amp;text=Speech%20is%20scheduled%20for%208,event%20also%20includes%20audience%20Q%26A">https://www.richmondfed.org/press_room/media_advisories/2025/20250623_barkin_ny#:~:text=Richmond%20Fed%20President%20Tom%20Barkin,%2C%202025%2C%20in%20New%20York.&amp;text=Speech%20is%20scheduled%20for%208,event%20also%20includes%20audience%20Q%26A</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Barkin Says Won't Take Any Action Off The Table But Does Seek More Data; Says Important To Defend Integrity Of Economic Data

UBS analyst Stephen Ju maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $683 to $812.

UBS Maintains Buy on Meta Platforms, Raises Price Target to $812

Fed's Daly Says My Modal Outlook Has Been For Some Time That We Would Begin To Be Able To Adjust The Rates In The Fall

Morgan Stanley analyst Rayna Kumar maintains SEI Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEIC#NASDAQ">SEIC</a>) with a Overweight and raises the price target from $84 to $100.

SEIC

Morgan Stanley Maintains Overweight on SEI Investments, Raises Price Target to $100

In the preceding three months, 4 analysts have released ratings for Applied Optoelectronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Applied Optoelectronics, revealing an average target of $25.5, a high estimate of $34.00, and a low estimate of $18.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 12.82%. 
<img src="https://www.benzinga.com/files/images/story/2025/1750946471_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Applied Optoelectronics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$34.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Simon Leopold</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$30.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Simon Leopold</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$31.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Applied Optoelectronics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Applied Optoelectronics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Applied Optoelectronics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Applied Optoelectronics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AAOI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Applied Optoelectronics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Applied Optoelectronics</h2>
Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.
<h3>Key Indicators: Applied Optoelectronics's Financial Health</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Applied Optoelectronics displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 145.52%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Applied Optoelectronics's net margin excels beyond industry benchmarks, reaching -9.19%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Applied Optoelectronics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -3.41%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Applied Optoelectronics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.54%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Applied Optoelectronics's debt-to-equity ratio is below the industry average. With a ratio of 0.62, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAOI

4 Analysts Assess Applied Optoelectronics: What You Need To Know

During the last three months, 12 analysts shared their evaluations of Citigroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $85.29, a high estimate of $100.00, and a low estimate of $75.50. A decline of 0.87% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1750946462_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Citigroup. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Richard Ramsden</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$78.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Scott Siefers</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$77.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>John McDonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$79.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>John McDonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$84.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Vivek Juneja</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$75.50</td>
<td>$85.50</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$89.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$76.00</td>
<td>$79.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Citigroup. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Citigroup compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Citigroup's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Citigroup's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/C/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Citigroup analyst ratings.</a>
<h2>Discovering Citigroup: A Closer Look</h2>
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
<h3>A Deep Dive into Citigroup's Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Positive Revenue Trend: Examining Citigroup's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 2.83% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Citigroup's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 17.36%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Citigroup's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 1.95%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Citigroup's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.15%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 1.78, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Citigroup Stock: Analyst Perspectives (12 Ratings)

4 analysts have expressed a variety of opinions on Haemonetics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $94.0, a high estimate of $105.00, and a low estimate of $84.00. Observing a downward trend, the current average is 11.6% lower than the prior average price target of $106.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1750946452_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Haemonetics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$87.00</td>
<td>-</td>
</tr>
<tr>
<td>David Turkaly</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Mike Matson</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$84.00</td>
<td>$104.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Haemonetics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Haemonetics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Haemonetics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Haemonetics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/HAE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Haemonetics analyst ratings.</a>
<h2>All You Need to Know About Haemonetics</h2>
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
<h3>Haemonetics: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Haemonetics's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -3.7%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Haemonetics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 17.54%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Haemonetics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.71% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Haemonetics's ROA excels beyond industry benchmarks, reaching 2.33%. This signifies efficient management of assets and strong financial health.
Debt Management: Haemonetics's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.49, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Haemonetics's Future

Econ #s

USA Pending Home Sales Index For May 72.6 Vs 71.3 Prior

Kura Sushi USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRUS#NASDAQ">KRUS</a>) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $60.43, a high estimate of $75.00, and a low estimate of $44.00. A decline of 22.66% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1750946437_0_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Kura Sushi USA by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$71.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Jon Tower</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Mark Smith</td>
<td>Lake Street</td>
<td>Lowers</td>
<td>Buy</td>
<td>$62.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$52.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$44.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Andrew Charles</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Hold</td>
<td>$72.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$75.00</td>
<td>$102.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kura Sushi USA. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Kura Sushi USA compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Kura Sushi USA's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of Kura Sushi USA's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KRUS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kura Sushi USA analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Kura Sushi USA</h2>
Kura Sushi USA Inc is a technology-enabled restaurant concept serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. It offers several dishes, including Dashi Olive Salmon, Tomago, Sweet Shrimp, Tuna, Garlic Tuna Steak, and Salmon, among others.
<h3>A Deep Dive into Kura Sushi USA's Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Kura Sushi USA's revenue growth over a period of 3M has been noteworthy. As of 28 February, 2025, the company achieved a revenue growth rate of approximately 13.27%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Kura Sushi USA's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -5.83%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Kura Sushi USA's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -1.67%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Kura Sushi USA's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.93%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.72, Kura Sushi USA adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KRUS

Analyst Expectations For Kura Sushi USA's Future

In the current market session, Ulta Beauty Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) stock price is at $453.09, after a 1.31% drop. However, over the past month, the company's stock spiked by 7.42%, and in the past year, by 17.42%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2025/1750946437_0.png" alt="Past Year Chart" />

<h3>How Does Ulta Beauty P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 49.97 in the Specialty Retail industry, Ulta Beauty Inc. has a lower P/E ratio of 17.95. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750946437_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

Markets

ULTA

A Look Into Ulta Beauty Inc's Price Over Earnings

SeaStar Medical Holding's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NYSE">ICU</a>) short percent of float has fallen 48.94% since its last report. The company recently reported that it has 79 thousand shares sold short, which is 0.72% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>SeaStar Medical Holding Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750946433_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for SeaStar Medical Holding has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing SeaStar Medical Holding's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, SeaStar Medical Holding's peer group average for short interest as a percentage of float is 9.48%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About SeaStar Medical Holding?

8 analysts have expressed a variety of opinions on Kymera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Kymera Therapeutics, presenting an average target of $60.5, a high estimate of $79.00, and a low estimate of $44.00. Witnessing a positive shift, the current average has risen by 14.78% from the previous average price target of $52.71.
<img src="https://www.benzinga.com/files/images/story/2025/1750946429_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Kymera Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Kalpit Patel</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>James Quigley</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Eric Joseph</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$64.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Alex Thompson</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$70.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Kymera Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Kymera Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Kymera Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Kymera Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/KYMR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Kymera Therapeutics analyst ratings.</a>
<h2>Get to Know Kymera Therapeutics Better</h2>
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
<h3>Kymera Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Kymera Therapeutics's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 114.83%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Kymera Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -296.75%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -8.09%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Kymera Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -6.92%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Kymera Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.11.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

WF Holding

Noticias

Últimas noticias sobre WF Holding (NASDAQ:WFF) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL